Karyopharm Therapeutics Inc. (KPTI)

Market Cap	38.59M
Revenue (ttm)	137.27M
Net Income (ttm)	-123.57M
Shares Out	8.67M
EPS (ttm)	-14.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,585
Open	4.110
Previous Close	4.020
Day's Range	4.110 - 4.500
52-Week Range	3.510 - 16.950
Beta	0.28
Analysts	Buy
Price Target	39.80 (+794.38%)
Earnings Date	Aug 11, 2025

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2024, Karyopharm Therapeutics's revenue was $145.24 million, a decrease of -0.55% compared to the previous year's $146.03 million. Losses were -$76.42 million, -46.60% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price target is $39.8, which is an increase of 794.38% from the latest price.

Price Target

$39.8

(794.38% upside)

Analyst Consensus: Buy